A Year at NCI: Harold Varmus Reflects On Provocative Questions, The Duke Scandal, Financial Disaster And Grant Review
Part One Of A Two-Part Interview With NCI Director Harold Varmus
Also: NCCN Committee Reaffirms Clinical Guideline Covering Avastin for Breast Cancer Indication
ODAC Votes For Accelerated Approval For Adcetris For Two Lymphoma Indications
Richard Pazdur’s Comments to ODAC
Department of Defense Offering $16 Million in Cancer Research Grants
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Did peer review fail? Nature Medicine’s chronotherapy paper retraction raises questions
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m. - OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill
- The future of oncology: Early-career scientists need mentorship and a new academic model









